Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/31080

Type
Article
Copyright
Restricted access
Embargo date
2028-08-30
Collections
Share

Statistics
Metadata
Show full item record

EFFICACY AND SAFETY OF DARUNAVIR-RITONAVIR AT WEEK 48 IN TREATMENT-EXPERIENCED PATIENTS WITH HIV-1 INFECTION IN POWER 1 AND 2: A POOLED SUBGROUP ANALYSIS OF DATA FROM TWO RANDOMISED TRIALS
Clotet, Bonaventura et al. | Date Issued: 2007
Author
Clotet, Bonaventura
Bellos, Nicholas
Molina, Jean-Michel
Cooper, David
Goffard, Jean-Christophe
Lazzarin, Adriano
Wöhrmann, Andrej
Katlama, Christine
Wilkin, Timothy
Haubrich, Richard
Cohen, Calvin
Farthing, Charles
Jayaweera, Dushyantha
Markowitz, Martin
Ruane, Peter
Spinosa-Guzman, Sabrina
Lefebvre, Eric
POWER 1 study group
POWER 2 study group
Affilliation
Hospital Universitari Germans Trias i Pujol and irsiCaixa Foundation. Barcelona, Catalonia, Spain.
Southwest Infectious Disease Associates. Dallas, TX, USA.
Hôpital St-Louis, Department of Infectious Disease, Assistance Publique. Paris, France.
St Vincent’s Hospital and University of New South Wales. Sydney, Australia.
Hôpital Universitaire Erasme. Brussels, Belgium.
San Raff aele University, Vita-Salute. Milan, Italy.
Klinik I für Innere Medizin der Universität de Köln. Cologne, Germany.
Hôpital Pitié-Salpêtrière. Paris, France.
Weill Medical College of Cornell University. New York, NY, USA.
University of California San Diego. San Diego, CA, USA.
Community Research Initiative of New England. Boston, MA, USA.
AIDS Healthcare Foundation Research Center. Beverly Hills, CA, USA.
University of Miami. Miami, FL, USA.
Rockefeller University Hospital, Aaron Diamond AIDS Research Center. New York, NY, USA.
Private Practice. Los Angeles, CA, USA.
Tibotec. Mechelen, Belgium.
Tibotec. Yardley, PA, USA.
Abstract
The continuing, randomised, multinational, phase IIB POWER 1 and 2 studies aim to evaluate efficacy and safety of darunavir in combination with low-dose ritonavir in treatment-experienced HIV-1-infected patients. We did a pooled subgroup analysis to update results at week 48 for patients receiving the recommended dose of darunavir-ritonavir compared with those receiving other protease inhibitors (PIs).
Keywords
HIV-1
Darunavir
Efficacy
Safety
Protease Inhibitors
Ritonavir
 
Publisher
Elsevier
Citation
CLOTET, B. et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet, v. 369, n. 9568, p. 1169-1178, 2007.
DOI
10.1016/S0140-6736(07)60497-8
ISSN
0140-6736
Notes
Presente no POWER 1 study seam: Beatriz Grinsztejn; Marília Santini (Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil).